Maykl C. Snabes, MD, PhD, vice president of the clinical development of the Pharmaceuticalses BioSante, will the hour the review of the key analytics in LibiGel progression inn a continuously ascending gradation (the gel testosterone) program inn Endocrine Society 90-e Annual Meeting in San Francisco in the Centre Moscone in Sunday, 15 June, 2008. The Announcement named ” Cardiovascular And Breast Safe Study Libigel In Woman with Sexual pharmacy pill mess of the Desire Hypoactive (HSDD): Project of the Analysis And Descriptions of the Endpoints,” - co-authored investigator and consultant in University America School Medicine, Consultants of the Berry, and M.D. The Cancerous Centre Anderson.

The Conference of the news will is organized in Sunday, 15 June, 2008, during which reporters invited to consider the announcement and discuss LibiGel and described analysis with Dr. Snabes.

BioSante CONDUCTS the safe analysis, inn post-woman menopausal with hypoactive sensuous health disorder of the desire (HSDD), without ceasing request USA. Food and Administration Medicine. The Request - in accordance with call to more safe agreed-upon from Endocrine Society, healing society to professions, which is convergent in endocrine and metabolic disease.

Dr. Snabes noted importance this preceding installing the analysis. “This clinical test to study the long-term effects testosterone in post-woman menopausal, can bee undivided of first big, cardiovascular operated events, studies pre- approvals were undertaken inn the absence of clear safe signal.”

BioSante EXPECTS that qualified and is tested aproximately threesome thousandth posts-womans menopausal between age fifty and eighty and, which has at least before one cardiovascular factor of the risk. The pharmacy online Primary safe result against this test - art effect of the processing in incidence heartily regardless, including cardiovascular bound death, heart attack, and blow. Incidence invasive breast cancer be a primary strongbox end co-, and investigators will also look the favourable breast breast cancer of the masses and non-invasives. The Patients will are evaluated proper for hirsutism, acne, and speech or reactions of the skin, as well as Temper testosterone be justify during each visit of the dissection.

HSDD be CHARACTERIZED low libido and the general defect of the interest in sex. If safe endpoints counter and approves the medicine, LibiGel will become first authorized processing specified for HSDD inn menopausal woman. BioSante EXPECTS the approval certain time during 2010 or 2011.

The Feminine sexual dysfunction can arise out of many reasons, including problems relations, use the pharmaceuticalses of the prescription, disease, or chemical imbalances. HSDD ADDRESSES successfully and successfully accompanying testosterone notwithstanding many years though and to date not approved for this consume. In terminated analysis Phase II LibiGel show excellent safety and expertise. However, newly became self-seeking cardiovascular and cancerous risk bound evident class medicine, amongst him potential therapy for FSD. The secured analysis of the Phase III be intended to confirm long-term safety LibiGel’s.

The Operated analysis studies the effect LibiGel inn post-woman drugstore online menopausal in dose 300 micrograms per diem over twelve months. BioSante is SPECIFICALLY focused in heartily event and incidence breast cancer. After twelve plans of the months BioSante two apply for approval through New Application Medicine (NDA). requires BioSante to conform to the group of the analysis during extra fourty-eight months, from subservience NDA and potential approval to compare mate the warmhearted event and breast cancer between group of the processing and corresponding to group of the womans, who get the gel

LibiGel - a gel 1% testosterone that woman enclose as soon as day, in their upper tumbler. Measured pea volume helium carries from head to foot skin quickly, from where he delivers the firm dose testosterone on blood.

Though testosterone thought-out as male hormone, he be also discovered in woman on level approaching with their age. The Researchers accept that testosterone will justify, what fall By the side of increasing of the age, can control the feminine sexual desire. For illustration, woman in her has I prep blood testosterone as woman in hits twenty.

Incidence HSDD also increases since age and after determined surgical procedures. Aproximately 14% premenopausal womans between age twenty and fourty-nine registered HSDD, in contrast Attending 26% womans, online pharmacy tablet who surgical have deleted their ovaries. Similarly, incidence HSDD grows before 9% for “naturally” menopausal womans. LibiGel is INTENDED too restore the level testosterone inn post-womans menopausal on level, which are considered normal to support sound libido.

The Results of the Analysis, pron carry the preceding safe information in the end must can be found to put the safe enxiety since processing testosterone in woman and lead to approval of the capital permissible, efficient processing was specifically indicated for HSDD in menopausal woman.